Policies Promoting Off-Patent Drugs Would Barely Cut Drug Prices In The US, CBO Says
The Report Analyzed Six Other Commonly Discussed Approaches To Reduce Drug Pricing
Along with other approaches, early market entry of generics and biosimilars would barely make a dent in reducing the net prices of retail prescription drugs in the US – but even then, small reductions would add up to billions, reveals the latest CBO calculation.
